CD274 and non-small cell lung carcinoma: A Phase III (NCT04746924) study is underway to assess the effectiveness of ociperlimab + tislelizumab, as opposed to pembrolizumab, in previously untreated patients with advanced NSCLC and PD-L1 tumor cell ≥ 50% expression [26].